A new tooth-regrowing drug has finally entered human trials after months of waiting and promising clinical trials on mice and ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Patients with disability often face considerable barriers when it comes to accessing clinical trials for new drugs and ...

Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...

The MSc in Clinical Drug Development provides students with a multidisciplinary perspective to facilitate their skills. The programme is designed for individuals who need an understanding of drug ...

T he US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab ...

Adverse drug reactions (ADRs) remain a common clinical problem since they can mimic many diseases and cause significant morbidity and mortality. Judicious prescribing is important to minimize ...

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after ...

From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

JSKN033-102 is an open-label, multicenter, Phase Ⅰ/Ⅱ clinical study designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and anti-tumor activity of JSKN033 in patients with ...

Even with another mid-stage setback, Roche believes there were enough positive signs to “merit further exploration” of the ...

Prothena's stock soared 34% despite setbacks, with promising partnerships and potential in Parkinson's and Alzheimer's ...